Search Results

We hope you find what you’re looking for. You can email us if you need additional help.

Optimi Health to advance psychedelic clinical trials

Story written by Stockhouse Optimi Health (CSE:OPTI) has signed a letter of intent with ATMA Journey Centers to advance its psilocybin extract into ATMA’s Phase II Psilocybin Clinical trial to treat major depressive disorder (MDD). While a definitive agreement will

Read More »

Products do not contain psilocybin

Search
Get news & updates directly to your inbox.
Interested In Optimi? Let's Talk.